Is Kythera's Double Chin Drug A Winner?

15:57 EDT 2 Apr 2013 | Seeking Alpha
ByC.R. Jackson:

One biotech company I am excited about is Kythera Biopharmaceuticals Inc. (KYTH). Kythera is developing ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, commonly known as "double chin."

Kythera's potential first-in-class injectable drug candidate is a proprietary formulation of synthetic deoxycholic acid, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue..

"Double chins" are caused by a layer of subcutaneous fat around the neck that sags down and creates a wrinkle, that has the resemblance of a second chin. Double chins are most commonly found on the elderly and the obese.

There are no drugs currently available to treat the fatty deposits that causes some double chins. People may opt

Complete Story »

Original Article: Is Kythera's Double Chin Drug A Winner?


More From BioPortfolio on "Is Kythera's Double Chin Drug A Winner?"

Search BioPortfolio:

Relevant Topics

Biotechnology - Biotech
Latest News Clinical Trials Research Drugs Reports Corporate
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Latest News Clinical Trials Research Drugs Reports Corporate
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...